Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

May 30, 2006

Primary Completion Date

March 16, 2012

Study Completion Date

December 10, 2012

Conditions
Blastic PhaseChildhood Acute Promyelocytic Leukemia With PML-RARAChildhood Chronic Myelogenous Leukemia, BCR-ABL1 PositiveChildhood Solid NeoplasmChronic Myelogenous Leukemia, BCR-ABL1 PositiveJuvenile Myelomonocytic LeukemiaPhiladelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous LeukemiaRecurrent Childhood Acute Lymphoblastic LeukemiaRecurrent Childhood Acute Myeloid LeukemiaRecurrent Disease
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

DRUG

Sorafenib Tosylate

Given orally

Trial Locations (25)

10032

Columbia University/Herbert Irving Cancer Center, New York

13210

State University of New York Upstate Medical University, Syracuse

15224

Children's Hospital of Pittsburgh of UPMC, Pittsburgh

19104

Children's Hospital of Philadelphia, Philadelphia

20010

Children's National Medical Center, Washington D.C.

20892

National Institutes of Health Clinical Center, Bethesda

35233

University of Alabama at Birmingham Cancer Center, Birmingham

38105

St. Jude Children's Research Hospital, Memphis

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

46202

Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis

Riley Hospital for Children, Indianapolis

48109

C S Mott Children's Hospital, Ann Arbor

53226

Children's Hospital of Wisconsin, Milwaukee

55455

University of Minnesota/Masonic Cancer Center, Minneapolis

60611

Lurie Children's Hospital-Chicago, Chicago

63110

Washington University School of Medicine, St Louis

75390

UT Southwestern/Simmons Cancer Center-Dallas, Dallas

77030

Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston

92868

Children's Hospital of Orange County, Orange

94304

Lucile Packard Children's Hospital Stanford University, Palo Alto

97239

Oregon Health and Science University, Portland

98105

Seattle Children's Hospital, Seattle

02215

Dana-Farber Cancer Institute, Boston

M5G 1X8

Hospital for Sick Children, Toronto

H3T 1C5

Centre Hospitalier Universitaire Sainte-Justine, Montreal

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT01445080 - Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia | Biotech Hunter | Biotech Hunter